Fig. 2

Time-course of the proportion of participants with pain freedom, MBS freedom, pain relief, and normal function from 15 minutes to 48 hours post-dose. Assessments were made at 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, and 48 h post-dose. Participants with missing data at the time point being assessed or who used rescue medication at or before the time point being assessed were imputed as failures (participants not reporting a MBS at migraine onset were imputed as failures in the MBS freedom analysis). *Nominal p <  0.05; based on the risk difference (rimegepant ODT vs. placebo). MBS, most bothersome symptom; ODT, orally disintegrating tablet